Sort   by:  
 Page size 
UnknownDysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination.
Not available
S-EPMC12501030 | biostudies-literature
UnknownSystems serology detects functionally distinct coronavirus antibody features in children and elderly.
Not available
S-EPMC8016934 | biostudies-literature
UnknownDurvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Not available
S-EPMC7771363 | biostudies-literature
UnknownEffects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Not available
S-EPMC7615589 | biostudies-literature
UnknownIdentification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Not available
S-EPMC2846760 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
Sort   by:  
 Page size